Predictive factors for early progression during induction chemotherapy and chemotherapy-free interval: analysis from PRODIGE 9 trial.
Fiche publication
Date publication
février 2020
Journal
British journal of cancer
Auteurs
Membres identifiés du Cancéropôle Est :
Dr BOREL Christian, Pr BOUCHE Olivier, Pr GHIRINGHELLI François, Pr LEPAGE Côme, Dr KAMINSKY Marie-Christine
Tous les auteurs :
Aparicio T, Bennouna J, Le Malicot K, Boige V, Taieb J, Bouché O, Phelip JM, François E, Borel C, Faroux R, Dahan L, Bachet JB, Egreteau J, Kaminsky MC, Gornet JM, Cojocarasu O, Gasmi M, Guerin-Meyer V, Lepage C, Ghiringhelli F,
Lien Pubmed
Résumé
Identifying patients with metastatic colorectal cancer who will have an early disease progression during induction chemotherapy (IC) and identifying patients who may have a chemotherapy-free interval (CFI) after IC are two major challenges.
Référence
Br. J. Cancer. 2020 Feb 4;: